Amgen's Blincyto puts leukemia patients in remission; Biogen confirms second PML case in Tecfidera patients;

> In a Phase II study, a "clinically meaningful" number of relapsed or refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia (ALL) patients taking Amgen's ($AMGN) Blincyto experienced complete remission or complete remission with partial hematological recovery. Release | Story

> Biogen ($BIIB) has confirmed the second case of rare brain disease progressive multifocal leukoencephalopathy (PML) among Tecfidera patients. More

> AstraZeneca ($AZN) has entered an agreement with Kyowa Hakko Kirin for an exclusive option to market current candidate drug benralizumab for asthma and COPD in Japan. Release

> Germany's price watchdog has reassessed the data on Novartis' ($NVS) MS pill Gilenya, and it's now recommending the treatment for more patients. Report

And Finally... Scientists believe they can use smartphones to identify people suffering depressive symptoms with 87% accuracy. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can AFib screening amp it up even more?